SCHEMBL681370

SCHEMBL681370

CCCCN(CCCC)CCCNC

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.55
PRMT3 O60678 1/20 0.38
CARM1 Q86X55 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
PRMT1 Q99873 1/20 0.38
PRMT8 Q9NR22 1/20 0.38
KDM5A P29375 4/20 0.37
PHF8 Q9UPP1 2/20 0.35
KDM4C Q9H3R0 2/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA9 Q16790 2/20 0.34
TSHR P16473 2/20 0.33
MAPT P10636 1/20 0.33
ALDH1A1 P00352 1/20 0.33
S100A4 P26447 1/20 0.33
HTR2A P28223 1/20 0.31
HRH1 P35367 1/20 0.31
DNM1 Q05193 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13867474 0.92 EPHX1 (0.59) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL29286833 0.90 EPHX1 (0.64) EPHX1KDM5APHF8KDM4CTSHR
SCHEMBL29286807 0.90 EPHX1 (0.64) EPHX1KDM5APHF8KDM4CTSHR
SCHEMBL24065809 0.90 EPHX1 (0.48) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL10811942 0.90 EPHX1 (0.48) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL681618 0.90 EPHX1 (0.48) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL21501557 0.90 EPHX1 (0.48) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL19607937 0.89 EPHX1 (0.44) EPHX1KDM5ATSHRMAPTALDH1A1
SCHEMBL15569827 0.89 PRMT3 (0.45) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL26678000 0.88 EPHX1 (0.54) EPHX1PRMT3CARM1PRMT6PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3864108-B1 UNSYMMETRICALLY SUBSTITUTED DICARBOXYLIC ACID DIAMIDO AMMONIUM SALTS AND THEIR USE FOR GAS HYDRATE ANTI-AGGLOMERATION CLARIANT INT LTD (CH) 2022-06-15 EP disclosed
US-9975930-B2 Lantibiotic derivatives and process for their preparation NAICONS S.R.L. (IT) 2018-05-22 US disclosed
WO-2017074971-A1 LIQUID DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2017-05-04 WO disclosed
US-20150274788-A1 LANTIBIOTIC DERIVATIVES AND PROCESS FOR THEIR PREPARATION NAICONS SRL (IT) 2015-10-01 US disclosed
US-20130122050-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2013-05-16 US disclosed
US-20130122050-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2013-05-16 US disclosed
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-04-11 US disclosed
US-20110052625-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2011-03-03 US disclosed
US-20110052625-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2011-03-03 US disclosed
US-20090269313-A1 ENCAPSULATION SYSTEM DIAKINE THERAPEUTICS, INC. (US) 2009-10-29 US disclosed
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2008-12-04 US disclosed
US-7393827-B2 Pharmaceutical compositions and methods for restoring β-cell mass and function DIAKINE THERAPEUTICS, INC. (US) 2008-07-01 US disclosed
US-7393827-B2 Pharmaceutical compositions and methods for restoring β-cell mass and function DIAKINE THERAPEUTICS, INC. (US) 2008-07-01 US disclosed
WO-2008011518-A2 ENCAPSULATION SYSTEM DIAKINE THERAPEUTICS, INC. (US) 2008-01-24 WO disclosed
WO-2007146786-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING B-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2007-12-21 WO disclosed
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-02-08 US disclosed
WO-2006074051-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2006-07-13 WO disclosed
US-5219480-A ETHYLENE ALPHA-OLEFIN MANNICH BASE VISCOSITY INDEX IMPROVER/DISPERSANT ADDITIVES DERIVED FROM AMINO PHENOLS AND MONOSECONDARY AMINES EXXON CHEMICAL PATENTS INC. (US) 1993-06-15 US disclosed
EP-0357215-A1 Ethylene alpha-olefin mannich base viscosity index improver/dispersant additives EXXON CHEMICAL PATENTS INC. (US) 1990-03-07 EP disclosed
US-3983248-A VIRICIDES RICHARDSON-MERRELL INC. (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130122050-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE IAPP, LITAF, IGF2BP1 EPHX1 3192/4885PRMT3 3859/4885CARM1 4682/4885
US-20110052625-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE IAPP, LITAF, IGF2BP1 EPHX1 2615/4885PRMT3 3996/4885CARM1 4611/4885
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS S100A4, S100A6, S100A10 EPHX1 2987/4885PRMT3 1752/4885CARM1 3867/4885
US-20090269313-A1 ENCAPSULATION SYSTEM GPR119, IAPP, LIPA EPHX1 3223/4885PRMT3 2985/4885CARM1 2245/4885
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment TP53, ACIN1, TP53BP1 EPHX1 3423/4885PRMT3 355/4885CARM1 1046/4885
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION IAPP, PNLIP, AMY2A EPHX1 1435/4885PRMT3 3363/4885CARM1 3045/4885
US-20150274788-A1 LANTIBIOTIC DERIVATIVES AND PROCESS FOR THEIR PREPARATION VIP, PCMT1, DLST EPHX1 4821/4885PRMT3 344/4885CARM1 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.